Claims
- 1. A method for inhibition of choroidal neovascularization comprising contacting the retinal pigmented epithelial cells of a subject in need thereof with a therapeutic amount of an AP-1 antagonist.
- 2. The method of claim 1 wherein the ocular disease is age-related macular degeneration.
- 3. The method of claim 1 wherein the ocular disease is histoplasmosis syndrome.
- 4. A method for inhibition of choroidal neovascularization comprising contacting the retinal pigmented epithelial cells of a subject in need thereof with a therapeutic amount of a retinoic acid receptor agonist, except for retinoic acid.
- 5. The method of claim 4 wherein the ocular disease is age-related macular degeneration.
- 6. The method of claim 4 wherein the ocular disease is histoplasmosis syndrome.
- 7. The method of claim 1 wherein the cells are further contacted with an additional anti-AP1 agent.
- 8. The method of claim 7 wherein the anti-AP1 agent is selected from the group consisting of dexamethasone, 1,25dhydroxy vitamin D.sub.3, and thyroid hormone.
- 9. The method of claim 4 wherein the retinoic acid receptor agonist is selected from the group consisting of ethyl-6-[2-(4,4-dethylthiochroman-6-yl)ethynyl]nicotinate, 6-[2-(4,4-dimethylchroman-6-yl)ethynyl]nicotinic acid, and p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzoic acid.
- 10. The method of claim 1, wherein the age related macular degeneration is substantially inhibited.
- 11. The method of claim 4, wherein the agonist is injected into the vitreous cavity.
- 12. The method of claim 11, wherein the therapeutic amount is in the range from about 50 .mu.g to about 150 .mu.g.
- 13. The method of claim 4, wherein the contacting is in a single dose administered within about 24 hours following surgery or trauma.
- 14. The method of claim 4, wherein the contacting is by slow release.
- 15. The method of claim 14, wherein the slow release is from about 3 to 20 days.
- 16. The method of claim 14, wherein the agonist is encapsulated into liposomes.
- 17. The method of claim 14, wherein the agonist is formulated for compaction into microparticles.
- 18. The method of claim 17, wherein the microparticulares are administered to the scleral pocket or subconjunctival space.
- 19. The method of claim 1, wherein the agonist is dissolved in a biologically inert liquid.
- 20. The method of claim 18, wherein the liquid is silicone oil.
Parent Case Info
This application is a International 371 of PCT/US96/01505 filed Jan. 31, 1996 and a continuation-in-part of U.S. Ser. No. 08/383,741, filed Feb. 1, 1995 now U.S. Pat. No. 5,824,685.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/US96/01505 |
1/31/1996 |
|
|
1/23/1998 |
1/23/1998 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO96/23498 |
8/8/1996 |
|
|
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5234926 |
Chandratna |
Aug 1993 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
383741 |
Feb 1995 |
|